MARKET

LQDA

LQDA

Liquidia Corporation
NASDAQ
43.04
+1.48
+3.56%
After Hours: 43.03 -0.01 -0.02% 19:54 02/06 EST
OPEN
42.65
PREV CLOSE
41.56
HIGH
43.89
LOW
41.79
VOLUME
1.50M
TURNOVER
--
52 WEEK HIGH
46.67
52 WEEK LOW
11.26
MARKET CAP
3.74B
P/E (TTM)
-30.0895
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LQDA last week (0126-0130)?
Weekly Report · 5d ago
Liquidia Reaches Analyst Target Price
NASDAQ · 01/30 14:08
Noteworthy Wednesday Option Activity: TBPH, APH, LQDA
NASDAQ · 01/28 20:20
Liquidia Unveils New Clinical Data on Inhaled Treprostinil Therapies at PVRI 2026 Congress
Reuters · 01/27 17:27
Liquidia To Highlight Clinical Data In Pulmonary Arterial Hypertension And PH-ILD With LIQ861 And L606 At PVRI 2026 Annual Congress
Benzinga · 01/27 13:32
Weekly Report: what happened at LQDA last week (0119-0123)?
Weekly Report · 01/26 09:12
Liquidia: Capturing Special Situation Gains And Longer-Term Gains
Seeking Alpha · 01/23 10:00
MRNA is S&P 500’s top performing stock, here are the best Quant pharma companies
Seeking Alpha · 01/21 19:36
More
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Webull offers Liquidia Corp stock information, including NASDAQ: LQDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LQDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LQDA stock methods without spending real money on the virtual paper trading platform.